Dexamethasone toxicity and quality of life in patients with brain metastases following palliative whole-brain radiotherapy

[1]  P. Wen,et al.  Epidemiology of Brain Metastases , 2012, Current Oncology Reports.

[2]  N. Yusoff,et al.  The Malay Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ C30): Reliability and Validity Study , 2010 .

[3]  D. Kondziolka,et al.  The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[4]  S. Sehlen,et al.  Effects of Radiotherapy for Brain Metastases on Quality of Life (QoL) , 2009, Strahlentherapie und Onkologie.

[5]  J. Bellmunt,et al.  Treatment of metastatic cancer , 2008 .

[6]  I. Tannock,et al.  Trials in palliative treatment--have the goal posts been moved? , 2008, The Lancet. Oncology.

[7]  G. Pond,et al.  The use and toxicity of steroids in the management of patients with brain metastases , 2008, Supportive Care in Cancer.

[8]  C. Ferrans.  Differences in what quality-of-life instruments measure. , 2007, Journal of the National Cancer Institute. Monographs.

[9]  J. Loeffler,et al.  Multidisciplinary management of brain metastases. , 2007, The oncologist.

[10]  S. Hassenbusch,et al.  A PILOT STUDY OF NEUROCOGNITIVE FUNCTION IN PATIENTS WITH ONE TO THREE NEW BRAIN METASTASES INITIALLY TREATED WITH STEREOTACTIC RADIOSURGERY ALONE , 2007, Neurosurgery.

[11]  E. Rakovitch,et al.  Whole brain radiotherapy for the treatment of multiple brain metastases. , 2006, The Cochrane database of systematic reviews.

[12]  P. Cornu,et al.  EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force , 2006, European journal of neurology.

[13]  Kimberly S. Chiew,et al.  Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy , 2005, British Journal of Cancer.

[14]  A. Bezjak,et al.  Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[15]  W. Curran,et al.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Hess,et al.  Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? , 2002, Supportive Care in Cancer.

[17]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[18]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[19]  A. Markoe,et al.  The Role of Steroids in the Management of Metastatic Carcinoma to the Brain: A Pilot Prospective Trial , 1994, American journal of clinical oncology.

[20]  W. van Putten,et al.  Dose‐effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors , 1994, Neurology.

[21]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[22]  B. Erickson,et al.  Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases , 1991, Journal of Neuro-Oncology.

[23]  Posner Jb.  Management of central nervous system metastases. , 1977 .

[24]  V. Vogel,et al.  Corticosteroid toxicity in neuro-oncology patients , 2007, Journal of Neuro-Oncology.

[25]  P. Fayers,et al.  The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. , 2006, European journal of cancer.

[26]  F. Liedberg,et al.  Noncontinent urinary diversion , 2006 .

[27]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .

[28]  J. Posner.  Management of central nervous system metastases. , 1977, Seminars in oncology.